Biogen Inc. $BIIB Shares Acquired by Investors Asset Management of Georgia Inc. GA ADV

Key Points

• Investors Asset Management of Georgia increased its Biogen stake by 811.3% in the third quarter, acquiring 8,373 additional shares for a total position worth approximately $2.1 million. Institutional investors collectively own 87.93% of BIIB.
• Biogen shares rose 4.5% to $243.88, near their 52-week high, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and a $239.96 price target.
• The company’s nephrology pipeline is gaining attention: long-term EMPAVELI data is expected to support adoption, while investigational felzartamab programs could provide future growth. However, safety warnings, clinical-trial risk and mixed insider activity remain concerns.

Investors Asset Management of Georgia Inc. GA ADV lifted its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 811.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,405 shares of the biotechnology company's stock after purchasing an additional 8,373 shares during the period. Investors Asset Management of Georgia Inc. GA ADV's holdings in Biogen were worth $2,124,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BIIB. Forum Financial Management LP lifted its holdings in Biogen by 2.4% during the 3rd quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company's stock worth $437,000 after buying an additional 46 shares in the last quarter. Wedbush Securities Inc. boosted its position in Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company's stock valued at $251,000 after buying an additional 56 shares during the period. Meeder Advisory Services Inc. grew its stake in shares of Biogen by 1.2% in the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock worth $866,000 after acquiring an additional 57 shares in the last quarter. Kera Capital Partners Inc. grew its stake in shares of Biogen by 3.5% in the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 58 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Biogen by 1.5% in the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company's stock worth $801,000 after acquiring an additional 65 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present 76-week EMPAVELI data at ASN Kidney Week showing sustained proteinuria reduction, stabilized kidney function, and a consistent long-term safety profile in C3G and primary IC-MPGN patients. The results reinforce confidence in EMPAVELI following its expanded FDA indication and could support broader commercial adoption. Biogen ASN Kidney Week announcement
• Positive Sentiment: Investors are also focusing on Biogen’s expanding nephrology strategy, including investigational felzartamab programs in antibody-mediated rejection, IgA nephropathy, and primary membranous nephropathy. Phase 3 data from the TRANSCEND study is expected in the first half of 2027, offering a potential longer-term pipeline catalyst.
• Positive Sentiment: Wells Fargo raised its Biogen price target from $250 to $310 and maintained an “overweight” rating, signaling increased confidence in the company’s earnings and pipeline outlook.
• Neutral Sentiment: Biogen is scheduled to report third-quarter 2026 results on October 28. The approaching earnings event may be increasing investor interest, although management’s outlook and commercial performance will determine whether the recent momentum continues.
• Neutral Sentiment: Institutional positioning was mixed: 523 investors added BIIB shares in the latest quarter, while 379 reduced positions. Several large funds made substantial purchases, but other institutions reported significant selling.
• Negative Sentiment: EMPAVELI carries a boxed warning for potentially fatal infections and requires a restricted REMS program, risks that could limit prescribing and complicate market uptake. Felzartamab also remains unapproved and dependent on successful clinical trials.
• Negative Sentiment: Recent insider activity included two sales and no purchases by insiders over the past six months. In addition, the reported median analyst price target of $223.50 is below the current trading level, suggesting some valuation caution despite the new Wells Fargo target.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Wolfe Research raised Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective on the stock in a research report on Thursday, August 13th. Bank of America decreased their target price on Biogen from $217.00 to $215.00 and set a "neutral" rating for the company in a report on Tuesday, July 21st. JPMorgan Chase & Co. upgraded Biogen from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $210.00 to $300.00 in a report on Monday, October 12th. Wall Street Zen cut Biogen from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Oppenheimer restated an "outperform" rating and set a $300.00 price target on shares of Biogen in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $239.96.

Biogen Stock Up 4.5%

Shares of BIIB traded up $10.40 during midday trading on Tuesday, reaching $243.88. The stock had a trading volume of 725,838 shares, compared to its average volume of 1,203,806. The company has a market cap of $36.03 billion, a price-to-earnings ratio of 43.19, a PEG ratio of 2.58 and a beta of 0.09. The company's fifty day simple moving average is $220.49 and its two-hundred day simple moving average is $204.32. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $244.65. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping analysts' consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company's revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts expect that Biogen Inc. will post 12.38 earnings per share for the current year.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.